Accessibility StatementSkip Navigation PHILADELPHIA, Dec. 1, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company") on behalf of investors who purchased MoonLake shares during the period of March 10, 2024 through September 29, 2025 (the "Class Period"). Investor Deadline: Investors who purchased MoonLake securities during the Class Period may, no later than December 15, 2025, ...

Core Insights - BellRing Brands, Inc. is under investigation for potential violations of federal securities laws, as announced by Bleichmar Fonti & Auld LLP [1] - The company's sales growth may have been artificially inflated due to temporary trade inventory loading rather than sustainable consumer demand [2] Company Performance - BellRing Brands operates in the convenient nutrition category, with key brands including Premier Protein and Dymatize, which offer ready-to-drink protein shakes and powders [2] - The company reported that Premier Protein achieved an all-time high in household penetration and strong demand across all channels, driven by distribution expansion and promotional activities [2] Stock Market Reaction - On May 5, 2025, BellRing disclosed that several key retailers reduced their inventory levels, which would negatively impact growth in Q3 2025. Following this announcement, the stock price dropped by $13.96, or over 18%, from $77.34 to $63.38 per share [3] - On August 4, 2025, the company announced disappointing quarterly consumption figures for Premier Protein RTD Shakes, leading to a further decline in stock price by $17.46, or nearly 33%, from $53.64 to $36.18 per share [4]

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Stride, Inc. (NYSE: LRN) and certain of the Company’s senior executives for securities fraud after significant stock drops resulting from the potential violations of the federal securities laws. If you invested in Stride, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/stride-inc-class-action-lawsuit. Inv ...

Core Viewpoint - A class action lawsuit has been filed against CarMax, Inc. and certain senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1][2]. Group 1: Lawsuit Details - Investors have until January 2, 2026, to request to lead the case, which is pending in the U.S. District Court for the District of Maryland [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of CarMax investors [2]. Group 2: Company Performance and Stock Impact - CarMax reported disappointing financial results for Q2 FY 2026, including a 5.4% decline in retail used unit sales, a 6.3% decline in comparable store used unit sales, and a 2.2% decline in wholesale units [5]. - The company's net income for Q2 was approximately $95.4 million, down from $132.8 million the previous year, attributed to a "pull forward" in demand due to U.S. tariffs [5]. - Following the financial report, CarMax's stock dropped $11.45 per share, or roughly 20%, from $57.05 on September 24, 2025, to $45.60 on September 25, 2025 [6]. - An unexpected departure of CEO Bill Nash on November 6, 2025, and a weak preliminary Q3 2025 outlook led to an additional stock drop of over 24% [6]. Group 3: Company Background - CarMax is a leading retailer of used cars, emphasizing a seamless customer experience and strong demand for its vehicles [3]. - The firm Bleichmar Fonti & Auld LLP, which is representing the plaintiffs, has a strong track record in securities class actions and has recovered significant amounts for other clients [10].

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Northern District of California, captioned Kim v. Synopsys, Inc., et al., No. 3:25-cv-09410 [3]. - Investors have until December 30, 2025, to request to be appointed to lead the case [3]. Group 2: Company Performance - Synopsys provides design automation software products, with its Design IP segment being the fastest-growing, increasing from 25% of revenue in 2022 to 31% in 2024 [4]. - The company reported a revenue of $425.9 million for its Design IP segment in Q3 2025, reflecting a 7.7% year-over-year decline, and a net income of $242.5 million, a 43% year-over-year decline [6]. Group 3: Market Reaction - Following the release of Q3 2025 financial results, Synopsys stock fell from $604.37 per share to $387.78 per share, a decline of nearly 36% [6]. - The decline was attributed to customers requiring more customization for IP components, which negatively impacted the economics of the Design IP business [5][6].

NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/moonlake-immunotherapeutics-class-action-lawsuit. Investors have until December 15, 2025, to as ...

Core Viewpoint - Firefly Aerospace Inc. is facing a class action lawsuit due to alleged violations of securities laws related to its initial public offering and subsequent financial disclosures, which reportedly misrepresented the company's operational readiness and financial performance [1][3]. Company Overview - Firefly Aerospace operates in the space and defense technology sector, providing mission solutions for national security, government, and commercial customers [2]. IPO Details - The company conducted its IPO on August 7, 2025, issuing approximately 19.3 million shares at an offering price of $45.00 per share [2]. Allegations of Misrepresentation - The lawsuit claims that Firefly Aerospace overstated demand and growth prospects for its Spacecraft Solutions offerings and the operational readiness of its Alpha rocket program, which could have a material negative impact once revealed [3]. Financial Performance - In its first earnings report as a public company on September 22, 2025, Firefly Aerospace reported a loss of $80.3 million for Q2 2025, compared to a loss of $58.7 million in Q2 2024. Revenue was reported at $15.55 million, below analyst estimates of $17.25 million, and down 26.2% year-over-year [4]. - The Spacecraft Solutions segment reported revenue of only $9.2 million, representing a 49% year-over-year decrease [4]. Stock Price Impact - Following the earnings report, Firefly Aerospace's stock price fell more than 15%. Additionally, on September 29, 2025, the company disclosed an issue with its Alpha Flight 7 rocket, leading to a further decline of over 20% in its stock price [4][5].

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by officers and directors of Blue Ridge Bankshares, Inc., which may affect shareholder rights and corporate governance [1][2]. Group 1: Shareholder Rights and Legal Options - Long-term shareholders of Blue Ridge Bank may seek corporate governance reforms, recovery of funds, court-approved financial incentives, or other benefits [2]. - Shareholder involvement is crucial for improving company policies and practices, leading to enhanced transparency and accountability, which can ultimately increase shareholder value [3]. Group 2: Firm's Background and Services - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors [4].

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of Agilon Health, Inc. (NYSE: AGL), urging shareholders to take action promptly due to possible time limitations on enforcing their rights [1]. Group 1: Shareholder Rights and Actions - Long-term shareholders of Agilon may seek corporate governance reforms, recovery of funds, court-approved financial incentives, or other benefits [2]. - Shareholder involvement is crucial for improving company policies and practices, leading to enhanced transparency, accountability, and overall shareholder value [3]. Group 2: Legal Representation and Firm Background - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors [4].

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of DexCom, Inc. which may affect shareholder rights [1][2]. Group 1: Shareholder Rights and Legal Options - Long-term shareholders of DexCom may seek corporate governance reforms, return of funds, court-approved financial incentives, or other benefits [2]. - Shareholder involvement is crucial for improving company policies and practices, enhancing transparency and accountability, which can ultimately increase shareholder value [3]. Group 2: Firm's Background and Services - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors [4].